UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis.

Authors:
Thompson Gana
Thompson Gana
University of Liverpool
Triantafillos Liloglou
Triantafillos Liloglou
University of Liverpool
United Kingdom
Adedamola Olayanju
Adedamola Olayanju
University of Liverpool
United Kingdom
Lawrence N Barrera
Lawrence N Barrera
University of East Anglia
United Kingdom
Robert Ferguson
Robert Ferguson
Union Memorial Hospital
United States
Fiona Campbell
Fiona Campbell
University of Liverpool
United Kingdom
Timothy Andrews
Timothy Andrews
University of York

J Pathol 2016 Feb 30;238(3):423-33. Epub 2015 Nov 30.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, UK.

The cellular defence protein Nrf2 is a mediator of oncogenesis in pancreatic ductal adenocarcinoma (PDAC) and other cancers. However, the control of Nrf2 expression and activity in cancer is not fully understood. We previously reported the absence of Keap1, a pivotal regulator of Nrf2, in ∼70% of PDAC cases. Here we describe a novel mechanism whereby the epigenetic regulator UHRF1 suppresses Keap1 protein levels. UHRF1 expression was observed in 20% (5 of 25) of benign pancreatic ducts compared to 86% (114 of 132) of pancreatic tumours, and an inverse relationship between UHRF1 and Keap1 levels in PDAC tumours (n = 124) was apparent (p = 0.002). We also provide evidence that UHRF1-mediated regulation of the Nrf2 pathway contributes to the aggressive behaviour of PDAC. Depletion of UHRF1 from PDAC cells decreased growth and enhanced apoptosis and cell cycle arrest. UHRF1 depletion also led to reduced levels of Nrf2-regulated downstream proteins and was accompanied by heightened oxidative stress, in the form of lower glutathione levels and increased reactive oxygen species. Concomitant depletion of Keap1 and UHRF1 restored Nrf2 levels and reversed cell cycle arrest and the increase in reactive oxygen species. Mechanistically, depletion of UHRF1 reduced global and tumour suppressor promoter methylation in pancreatic cancer cell lines, and KEAP1 gene promoter methylation was reduced in one of three cell lines examined. Thus, methylation of the KEAP1 gene promoter may contribute to the suppression of Keap1 protein levels by UHRF1, although our data suggest that additional mechanisms need to be explored. Finally, we demonstrate that K-Ras drives UHRF1 expression, establishing a novel link between this oncogene and Nrf2-mediated cellular protection. Since UHRF1 over-expression occurs in other cancers, its ability to regulate the Keap1-Nrf2 pathway may be critically important to the malignant behaviour of these cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738372PMC
February 2016
9 Reads

Publication Analysis

Top Keywords

uhrf1
11
levels uhrf1
8
uhrf1 expression
8
reactive oxygen
8
oxygen species
8
protein levels
8
depletion uhrf1
8
cell cycle
8
cycle arrest
8
cell lines
8
promoter methylation
8
keap1 protein
8
keap1 gene
8
gene promoter
8
keap1-nrf2 pathway
8
pancreatic cancer
8
keap1
7
levels
6
nrf2
5
pdac
5

Similar Publications

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.

Mol Cancer 2011 Apr 13;10:37. Epub 2011 Apr 13.

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, UK.

Background: Nrf2 is a key transcriptional regulator of a battery of genes that facilitate phase II/III drug metabolism and defence against oxidative stress. Nrf2 is largely regulated by Keap1, which directs Nrf2 for proteasomal degradation. The Nrf2/Keap1 system is dysregulated in lung, head and neck, and breast cancers and this affects cellular proliferation and response to therapy. Read More

View Article
April 2011

Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.

Free Radic Biol Med 2015 Dec 25;89:209-19. Epub 2015 Sep 25.

Department of Toxicology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou, Jiangsu 215123, People's Republic of China. Electronic address:

It is well known that long-term exposure to arsenite leads to human skin cancer, but the underlying mechanisms of carcinogenesis remain obscure. The transcription factor Nrf2-mediated antioxidant response represents a critical cellular defense mechanism; however, emerging data suggest that constitutive activation of Nrf2 is associated with cancer development and chemotherapy resistance. The reasons Nrf2 continuously accumulates in cancer cells remain to be fully understood. Read More

View Article
December 2015

Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.

Clin Cancer Res 2015 Oct 15;21(20):4719-32. Epub 2015 Jun 15.

Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan. Graduate Institute of Biomedical Sciences, College of Life Science, National Taiwan University, Taipei, Taiwan.

Purpose: Kelch-like ECH-associated protein 1 (Keap1) is an E3 ligase participated in the cellular defense response against oxidative stress through nuclear factor erythroid-2-related factor 2 (Nrf2). However, the role of Keap1 in regulating cancer motility is still controversial. We investigated the contribution of the Keap1-Nrf2 axis in the progression of non-small cell lung cancer (NSCLC). Read More

View Article
October 2015

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

Nature 2011 Jul 6;475(7354):106-9. Epub 2011 Jul 6.

Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK.

Reactive oxygen species (ROS) are mutagenic and may thereby promote cancer. Normally, ROS levels are tightly controlled by an inducible antioxidant program that responds to cellular stressors and is predominantly regulated by the transcription factor Nrf2 (also known as Nfe2l2) and its repressor protein Keap1 (refs 2-5). In contrast to the acute physiological regulation of Nrf2, in neoplasia there is evidence for increased basal activation of Nrf2. Read More

View Article
July 2011